Since it was costly and complex for clinical application, the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE), which is simple and suitable in clinical practice, was developed and stratified EC into 4 subgroups: (i) mismatch repair deficient (MMR-D), showing the loss of one or more mismatch repair protein(s); (ii) DNA polymerase epsilon (POLE), with mutations in the exonuclease domain in exons 9–14, is associated with very favorable outcomes; (iii) p53 abnormal (p53abn) demonstrating aberrant p53 immunohistochemical staining; and (iv) p53 wild type (p53wt) (10). This evidence concerns the gene POLE and endometrial cancer.